Reduced folate carrier (RFC) as a predictive marker for response to pemetrexed in advanced non-small cell lung cancer (NSCLC)

Author： Alvarez-Fernandez Carlos   Perez-Arnillas Quionia   Ruiz-Echeverria Lucrecia   Rodriguez-Rubi David   Sanchez-Lorenzo Luisa   Li-Torres Walter   Izquierdo-Manuel Marta   Berros Jose   Luque-Cabal Maria   Jimenez-Fonseca Paula   Villanueva-Palicio Noemi   Esteban-Gonzalez Emilio  

Publisher： Springer Publishing Company

ISSN： 0167-6997

Source： Investigational New Drugs, Vol.32, Iss.2, 2014-04, pp. : 377-381

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Pemetrexed in advanced non-small cell lung cancer

By Gridelli Cesare   Maione Paolo   Rossi Antonio   Bareschino Maria Anna   Schettino Clorinda   Sacco Paola Claudia   Zeppa Rosario  

Expert Opinion on Drug Safety, Vol. 10, Iss. 2, 2011-03 ,pp. : 311-317

Informa Healthcare

Access to resources Recommend Favorite

Pemetrexed for the treatment of non-small cell lung cancer

By Genova Carlo  

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 11, 2013-08 ,pp. : 1545-1558

Informa Healthcare

Access to resources Recommend Favorite

Pharmacological Aspects of the Enzastaurin-Pemetrexed Combination in Non-Small Cell Lung Cancer (NSCLC)

By  

Current Drug Targets, Vol. 11, Iss. 1, 2010-01 ,pp. : 12-28

Bentham Science Publishers

Access to resources Recommend Favorite

Pemetrexed: A Review of its Use in the Management of Advanced Non-Squamous Non-Small Cell Lung Cancer

By Baldwin Claudine M.   Perry Caroline M.  

Drugs, Vol. 69, Iss. 16, 2009-11 ,pp. : 2279-2302

Adis International

Access to resources Recommend Favorite

The Role of Pemetrexed in Second-Line Chemotherapy for Advanced Non-Small Cell Lung Cancer

By  

Current Drug Targets, Vol. 11, Iss. 1, 2010-01 ,pp. : 58-60

Bentham Science Publishers

Access to resources Recommend Favorite